Myelodysplastic syndromes

Common Name(s)

Myelodysplastic syndromes, MYELODYSPLASTIC SYNDROME

Myelodysplastic syndromes (MDS) are a rare group of blood disorders characterized by abnormal development of blood cells within the bone marrow. Individuals with MDS have abnormally low blood cell levels (low blood counts). Signs and symptoms associated with MDS include dizziness, fatigue, weakness, shortness of breath, bruising and bleeding, frequent infections, and headaches. In some cases, MDS may progress to bone marrow failure or an acute leukemia. The exact cause of MDS is unknown. It sometimes runs in families, but no disease-causing gene has been identified. Treatment depends on the affected individual's age, general health, and type of MDS and may include red cell and/or platelet transfusions and antibiotics.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Myelodysplastic syndromes" for support, advocacy or research.

Logo
Aplastic Anemia & MDS International Foundation

The Aplastic Anemia & MDS International Foundation (AA&MDSIF) is the world's leading nonprofit health organization dedicated to supporting patients and families living with aplastic anemia, myelodysplastic syndromes (MDS), paroxysmal nocturnal hemoglobinuria (PNH), and related bone marrow failure diseases. AA&MDSIF provides answers, support and hope to thousands of patients and their families around the world.

Last Updated: 29 Apr 2014

View Details
National Bone Marrow Transplant Link

The mission of the National Bone Marrow Transplant Link is to help patients, caregivers, and families cope with the social and emotional challenges of bone marrow/stem cell transplant from diagnosis through survivorship by providing vital information and personalized support services.

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Myelodysplastic syndromes" for support, advocacy or research.

Logo
Aplastic Anemia & MDS International Foundation

The Aplastic Anemia & MDS International Foundation (AA&MDSIF) is the world's leading nonprofit health organization dedicated to supporting patients and families living with aplastic anemia, myelodysplastic syndromes (MDS), paroxysmal nocturnal hemoglobinuria (PNH), and related bone marrow failure diseases. AA&MDSIF provides answers, support and hope to thousands of patients and their families around the world.

http://www.aamds.org/

Last Updated: 29 Apr 2014

View Details
National Bone Marrow Transplant Link

The mission of the National Bone Marrow Transplant Link is to help patients, caregivers, and families cope with the social and emotional challenges of bone marrow/stem cell transplant from diagnosis through survivorship by providing vital information and personalized support services.

http://www.nbmtlink.org

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Myelodysplastic syndromes" returned 609 free, full-text research articles on human participants. First 3 results:

The level of bone marrow WT1 message is a useful marker to differentiate myelodysplastic syndromes with low blast percentage from cytopenia due to other reasons.
 

Author(s): Maki Baba, Tomoko Hata, Hideki Tsushima, Sayaka Mori, Daisuke Sasaki, Kazuto Turuta, Hiroo Hasegawa, Koji Ando, Yasushi Sawayama, Daisuke Imanishi, Jun Taguchi, Katsunori Yanagihara, Masao Tomonaga, Shimeru Kamihira, Yasushi Miyazaki

Journal: Intern. Med.. 2015 ;54(5):445-51.

 

Myelodysplastic syndromes (MDS) are a group of hematological neoplasms associated with ineffective hematopoiesis and that transform to acute leukemia. Distinguishing MDS from other cytopenias is sometimes difficult even for trained hematologists. WT1, the gene mutated in Wilms' tumor, ...

Last Updated: 11 Mar 2015

Go To URL
Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes.
 

Author(s): Yogen Saunthararajah, Mikkael Sekeres, Anjali Advani, Reda Mahfouz, Lisa Durkin, Tomas Radivoyevitch, Ricki Englehaupt, Joy Juersivich, Kathleen Cooper, Holleh Husseinzadeh, Bartlomiej Przychodzen, Matthew Rump, Sean Hobson, Marc Earl, Ronald Sobecks, Robert Dean, Frederic Reu, Ramon Tiu, Betty Hamilton, Edward Copelan, Alan Lichtin, Eric Hsi, Matt Kalaycio, Jaroslaw Maciejewski

Journal: J. Clin. Invest.. 2015 Mar;125(3):1043-55.

 

Mutational inactivation in cancer of key apoptotic pathway components, such as TP53/p53, undermines cytotoxic therapies that aim to increase apoptosis. Accordingly, TP53 mutations are reproducibly associated with poor treatment outcomes. Moreover, cytotoxic treatments destroy normal ...

Last Updated: 3 Mar 2015

Go To URL
[The clinical efficacy of the patients of acute myeloid leukemia and myelodysplastic syndromes treated with decitabine alone, combined with half or one couse of CAG regimen].
 

Author(s): Su Gao, Huiying Qiu, Zhengming Jin, Xiaowen Tang, Zhengzheng Fu, Xiao Ma, Yue Han, Suning Chen, Aining Sun, Depei Wu

Journal: Zhonghua Xue Ye Xue Za Zhi. 2014 Nov;35(11):961-5.

 

To observe the clinical safety and efficacy of decitabine in patients of acute myeloid leukemia and myelodysplastic syndromes (MDS/AML).

Last Updated: 24 Nov 2014

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Myelodysplastic syndromes" returned 126 free, full-text review articles on human participants. First 3 results:

Frequent chromatin rearrangements in myelodysplastic syndromes--what stands behind?
 

Author(s): E Pagáčová, M Falk, I Falková, E Lukášová, K Michalová, A Oltová, I Raška, S Kozubek

Journal: Folia Biol. (Praha). 2014 ;60 Suppl 1():1-7.

 

Myelodysplastic syndromes (MDS) represent a clinically and genetically heterogeneous group of clonal haematopoietic diseases characterized by a short survival and high rate of transformation to acute myeloid leukaemia (AML). In spite of this variability, MDS is associated with typical ...

Last Updated: 5 Nov 2014

Go To URL
The challenging world of cytopenias: distinguishing myelodysplastic syndromes from other disorders of marrow failure.
 

Author(s): Amy E DeZern, Mikkael A Sekeres

Journal: Oncologist. 2014 Jul;19(7):735-45.

 

Over the past decade, our understanding of bone marrow failure has advanced considerably. Marrow failure encompasses multiple overlapping diseases, and there is increasing availability of diagnostic tools to distinguish among the subtypes. Identification of genetic alterations that ...

Last Updated: 2 Jul 2014

Go To URL
MicroRNAs in the pathogenesis of myelodysplastic syndromes and myeloid leukaemia.
 

Author(s): Su Jung Song, Pier Paolo Pandolfi

Journal: Curr. Opin. Hematol.. 2014 Jul;21(4):276-82.

 

This review highlights recent insights into the roles of microRNAs (miRNAs) in pathogenesis of myeloid malignancies and tantalising prospects of miRNA therapy.

Last Updated: 6 Jun 2014

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant
 

Status: Recruiting

Condition Summary: Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Secondary Myelodysplastic Syndrome

 

Last Updated: 29 Apr 2015

Go to URL
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
 

Status: Recruiting

Condition Summary: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Chronic Myelomonocytic Leukemia; Previously Treated Myelodysplastic Syndrome; Recurrent Adult Acute Myeloid Leukemia; Secondary Myelodysplastic Syndrome

 

Last Updated: 27 Aug 2015

Go to URL
Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy
 

Status: Recruiting

Condition Summary: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); de Novo Myelodysplastic Syndromes; Myelodysplastic Syndrome With Isolated Del(5q); Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Myeloid Leukemia

 

Last Updated: 24 Mar 2015

Go to URL